23andMe, a prominent DNA testing firm, has filed for bankruptcy as part of a process to potentially sell itself. This has sparked discussions among users regarding the implications of their personal genetic data becoming part of the assets available for sale to bidders. Concerns have been raised about privacy and the ethical considerations of data ownership in the event of a sale, especially given the sensitive nature of genetic information. Additionally, inquiries have arisen about the procedural aspects of corporate bankruptcy in the US, particularly regarding how assets like genetic data might be handled and whether they can be sold together or piecemeal.